BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 12143270)

  • 1. [Immunogenicity and reactogenicity of a reduced antigen content diphtheria, tetanus and acellular pertussis vaccine dTpa) in 10 to 11 years old children and in adults].
    Abarca K; Valdivieso F; Potin M; Ibáñez I; Vial P
    Rev Med Chil; 2002 May; 130(5):502-10. PubMed ID: 12143270
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunogenicity and reactogenicity of a reduced-antigen-content diphtheria-tetanus-acellular pertussis vaccine as a single-dose booster in Singaporean adults.
    Chan SH; Tan PT; Han HH; Bock HL
    Singapore Med J; 2006 Apr; 47(4):286-90. PubMed ID: 16572239
    [TBL] [Abstract][Full Text] [Related]  

  • 3. One-year post-primary antibody persistence and booster immune response to a fully liquid five-component acellular pertussis, diphtheria, tetanus, inactivated poliomyelitis, Haemophilus influenzae type b conjugate vaccine.
    Lin TY; Wang YH; Huang YC; Chiu CH; Lin PY; Chen CJ; Chavand P; Ortiz E
    Int J Infect Dis; 2007 Nov; 11(6):488-95. PubMed ID: 17349809
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessment of nine candidate DTP-vaccines with reduced amount of antigen and/or without adjuvant as a fourth (booster-) dose in the second year of life.
    Knuf M; Habermehl P; Faber J; Bock HL; Sänger R; Bogaerts H; Clemens R; Schuind A; du Prel JB; Schmitt HJ
    Vaccine; 2006 Jul; 24(27-28):5627-36. PubMed ID: 16740348
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunogenicity and reactogenicity of a reduced-antigen-content diphtheria-tetanus-acellular pertussis vaccine in healthy Taiwanese children and adolescents.
    Huang LM; Chang LY; Tang H; Bock HL; Lu CY; Huang FY; Lin TY; Lee CY
    J Adolesc Health; 2005 Dec; 37(6):517. PubMed ID: 16310132
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomised controlled trial with a diphtheria-tetanus-acellular pertussis (dTpa) vaccine in adults.
    Van der Wielen M; Van Damme P; Joossens E; François G; Meurice F; Ramalho A
    Vaccine; 2000 Apr; 18(20):2075-82. PubMed ID: 10715521
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Booster vaccination of adults with reduced-antigen-content diphtheria, Tetanus and pertussis vaccine: immunogenicity 5 years post-vaccination.
    McIntyre PB; Burgess MA; Egan A; Schuerman L; Hoet B
    Vaccine; 2009 Feb; 27(7):1062-6. PubMed ID: 19095033
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunogenicity of the reduced-antigen-content dTpa vaccine (Boostrix(®)) in adults 55 years of age and over: a sub-analysis of four trials.
    Van Damme P; McIntyre P; Grimprel E; Kuriyakose S; Jacquet JM; Hardt K; Messier M; Van Der Meeren O
    Vaccine; 2011 Aug; 29(35):5932-9. PubMed ID: 21718738
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An adolescent-adult formulation tetanus and diptheria toxoids adsorbed combined with acellular pertussis vaccine has comparable immunogenicity but less reactogenicity in children 4-6 years of age than a pediatric formulation acellular pertussis vaccine and diphtheria and tetanus toxoids adsorbed combined with inactivated poliomyelitis vaccine.
    Langley JM; Predy G; Guasparini R; Law B; Diaz-Mitoma F; Whitstitt P; Tapiero B; Dionne M; Tomovici A; Mills E; Halperin SA
    Vaccine; 2007 Jan; 25(6):1121-5. PubMed ID: 17045366
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessment of safety and efficacy against Bordetella pertussis of a new tetanus-reduced dose diphtheria-acellular pertussis vaccine in a murine model.
    Kwon HJ; Han SB; Kim BR; Kang KR; Huh DH; Choi GS; Ahn DH; Kang JH
    BMC Infect Dis; 2017 Apr; 17(1):247. PubMed ID: 28376777
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Decennial administration of a reduced antigen content diphtheria and tetanus toxoids and acellular pertussis vaccine in young adults.
    Mertsola J; Van Der Meeren O; He Q; Linko-Parvinen A; Ramakrishnan G; Mannermaa L; Soila M; Pulkkinen M; Jacquet JM
    Clin Infect Dis; 2010 Sep; 51(6):656-62. PubMed ID: 20704493
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and immunogenicity of a primary course and booster dose of a combined diphtheria, tetanus, acellular pertussis, hepatitis B and inactivated poliovirus vaccine.
    Meriste S; Lutsar I; Tamm E; Willems P
    Scand J Infect Dis; 2006; 38(5):350-6. PubMed ID: 16709537
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Booster vaccination of toddlers with reduced antigen content diphtheria -- tetanus -- acellular pertussis vaccine.
    Nolan T; Ruff TA; Lambert SB; Buttery J; O'Grady KA; Streeton C; Hoet B; Bock HL
    Vaccine; 2009 Apr; 27(18):2410-3. PubMed ID: 19368781
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomised, double-blind, non-inferiority clinical trial on the safety and immunogenicity of a tetanus, diphtheria and monocomponent acellular pertussis (TdaP) vaccine in comparison to a tetanus and diphtheria (Td) vaccine when given as booster vaccinations to healthy adults.
    Thierry-Carstensen B; Jordan K; Uhlving HH; Dalby T; Sørensen C; Jensen AM; Heilmann C
    Vaccine; 2012 Aug; 30(37):5464-71. PubMed ID: 22776216
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunogenicity and safety of a DTaP-IPV//PRP-T vaccine (Pentaxim) booster during the second year of life in Thai children primed with an acellular pertussis combined vaccine.
    Thisyakorn U; Pancharoen C; Chuenkitmongkol S; Ortiz E
    Southeast Asian J Trop Med Public Health; 2009 Mar; 40(2):282-94. PubMed ID: 19323013
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diphtheria-tetanus-acellular pertussis and inactivated poliovirus vaccines given separately or combined for booster dosing at 4-6 years of age.
    Black S; Friedland LR; Ensor K; Weston WM; Howe B; Klein NP
    Pediatr Infect Dis J; 2008 Apr; 27(4):341-6. PubMed ID: 18316985
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combined reduced-antigen-content diphtheria-tetanus-acellular pertussis and polio vaccine (dTpa-IPV) for booster vaccination of adults.
    Grimprel E; von Sonnenburg F; Sänger R; Abitbol V; Wolter JM; Schuerman LM
    Vaccine; 2005 May; 23(28):3657-67. PubMed ID: 15882526
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High levels of antibody in adults three years after vaccination with a reduced antigen content diphtheria-tetanus-acellular pertussis vaccine.
    McIntyre PB; Turnbull FM; Egan AM; Burgess MA; Wolter JM; Schuerman LM
    Vaccine; 2004 Dec; 23(3):380-5. PubMed ID: 15530684
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Acellular pertussis vaccine booster combined with diphtheria and tetanus toxoids for adolescents.
    Pichichero ME; Blatter MM; Kennedy WA; Hedrick J; Descamps D; Friedland LR
    Pediatrics; 2006 Apr; 117(4):1084-93. PubMed ID: 16585302
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunogenicity, reactogenicity and safety of a 7-valent pneumococcal conjugate vaccine (PCV7) concurrently administered with a DTPa-HBV-IPV/Hib combination vaccine in healthy infants.
    Knuf M; Habermehl P; Cimino C; Petersen G; Schmitt HJ
    Vaccine; 2006 May; 24(22):4727-36. PubMed ID: 16616973
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.